United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at approximately $168,188,006.77. This trade represents a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

United Therapeutics Price Performance

NASDAQ UTHR opened at $512.88 on Tuesday. The company’s 50 day simple moving average is $532.35 and its 200 day simple moving average is $538.04. United Therapeutics Corporation has a 12 month low of $302.19 and a 12 month high of $609.35. The company has a market capitalization of $22.00 billion, a P/E ratio of 18.35, a PEG ratio of 1.74 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the firm posted $6.41 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

Institutional Trading of United Therapeutics

Several large investors have recently added to or reduced their stakes in UTHR. Torren Management LLC purchased a new stake in shares of United Therapeutics in the fourth quarter valued at $26,000. Toth Financial Advisory Corp raised its position in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 48 shares during the period. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics in the 2nd quarter worth about $30,000. Finally, WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on UTHR. Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Weiss Ratings upgraded United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, August 13th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, JPMorgan Chase & Co. boosted their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.